Clinical Trials Logo

Clinical Trial Summary

The primary study objective is to assess the safety of afamelanotide while the secondary objective is to assess whether the therapy affects the size of the penumbra, by increasing blood flow, restoring oxygen supply to the brain, and reducing the amount of cerebral oedema (fluid) which is seen as a result of the stroke. Positive findings would indicate that the drug is able to support brain tissue-at-risk and provide overall neuroprotection and benefit to stroke patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04962503
Study type Interventional
Source Clinuvel Pharmaceuticals Limited
Contact
Status Completed
Phase Phase 2
Start date June 3, 2021
Completion date February 4, 2022

See also
  Status Clinical Trial Phase
Withdrawn NCT03249844 - Paediatric Arteriopathy Steroid Aspirin Project Phase 3
Enrolling by invitation NCT06040255 - Focal Cerebral Arteriopathy Steroid Trial Phase 4
Completed NCT03887143 - National Retrospective Study Of Recanalization Treatments In Pediatric Arterial Ischemic Stroke